Leland Gershell
Stock Analyst at Oppenheimer
(4.52)
# 242
Out of 5,170 analysts
158
Total ratings
48.99%
Success rate
30.14%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $110 → $80 | $33.31 | +140.17% | 10 | Mar 18, 2026 | |
| ENGN enGene Holdings | Maintains: Outperform | $33 → $30 | $7.32 | +310.12% | 4 | Mar 11, 2026 | |
| OCGN Ocugen | Initiates: Outperform | $10 | $2.09 | +379.62% | 1 | Mar 11, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $125 → $145 | $77.47 | +87.17% | 3 | Mar 9, 2026 | |
| CALC CalciMedica | Maintains: Outperform | $20 → $10 | $0.69 | +1,341.34% | 6 | Mar 5, 2026 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $35 → $21 | $4.30 | +388.37% | 2 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $98 → $95 | $54.27 | +75.05% | 4 | Feb 24, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $246 → $262 | $225.36 | +16.26% | 13 | Feb 12, 2026 | |
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $61.02 | +363.78% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $30.66 | +76.13% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $24 | $10.71 | +124.09% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.52 | +226.09% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $27.43 | +31.24% | 7 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $73 → $87 | $35.69 | +143.80% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $30.51 | +162.21% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $68.29 | -10.68% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $317.58 | +54.29% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.65 | +253.98% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $89.24 | +23.26% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $17.62 | +75.94% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $6.50 | +53.85% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $673.39 | +5.14% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $0.09 | +11,023.47% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $209.14 | -29.71% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.27 | +2,107.51% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $23.53 | +125.24% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.73 | +221.72% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $1.66 | +301,104.82% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.30 | +371.70% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.68 | +27.87% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $13.73 | +154.92% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.26 | +3,676.44% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.59 | +3,289.83% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.44 | +802.78% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.41 | +2,621.09% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.60 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $28.94 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.89 | - | 5 | Mar 31, 2020 |
Soleno Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $110 → $80
Current: $33.31
Upside: +140.17%
enGene Holdings
Mar 11, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $7.32
Upside: +310.12%
Ocugen
Mar 11, 2026
Initiates: Outperform
Price Target: $10
Current: $2.09
Upside: +379.62%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Outperform
Price Target: $125 → $145
Current: $77.47
Upside: +87.17%
CalciMedica
Mar 5, 2026
Maintains: Outperform
Price Target: $20 → $10
Current: $0.69
Upside: +1,341.34%
Aardvark Therapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $35 → $21
Current: $4.30
Upside: +388.37%
BioMarin Pharmaceutical
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $54.27
Upside: +75.05%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $225.36
Upside: +16.26%
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $61.02
Upside: +363.78%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $30.66
Upside: +76.13%
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $10.71
Upside: +124.09%
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $5.52
Upside: +226.09%
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $27.43
Upside: +31.24%
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $35.69
Upside: +143.80%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $30.51
Upside: +162.21%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $68.29
Upside: -10.68%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $317.58
Upside: +54.29%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $5.65
Upside: +253.98%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $89.24
Upside: +23.26%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $17.62
Upside: +75.94%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $6.50
Upside: +53.85%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $673.39
Upside: +5.14%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $0.09
Upside: +11,023.47%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $209.14
Upside: -29.71%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.27
Upside: +2,107.51%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $23.53
Upside: +125.24%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.73
Upside: +221.72%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $1.66
Upside: +301,104.82%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.30
Upside: +371.70%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.68
Upside: +27.87%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $13.73
Upside: +154.92%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.26
Upside: +3,676.44%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.59
Upside: +3,289.83%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.44
Upside: +802.78%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.41
Upside: +2,621.09%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.60
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $28.94
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.89
Upside: -